All the news Showing 10 of 64 articles from: Ns5A inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Six-week oral treatment can cure hard-to-treat hepatitis C patients Liz Highleyman / 12 March 2014 Interferon- and ribavirin-free treatment using sofosbuvir, ledipasvir and a third direct-acting drug for as little as six weeks can cure most previously untreated people with genotype 1 hepatitis C virus (HCV), including those ... Daclatasvir + sofosbuvir shows high hep C cure rate, new studies underway Liz Highleyman / 22 January 2014 A dual oral regimen of daclatasvir plus sofosbuvir cured more than 90% of chronic hepatitis C patients without interferon or ribavirin, according to a report in the January 16, 2014, New England Journal of ... Gilead two-drug hep C combination cures 94% of genotype 1 patients in 8 weeks Keith Alcorn / 18 December 2013 A two-drug combination of sofosbuvir and ledipasvir cured 94% of previously untreated patients with genotype 1 hepatitis C infection after 8 weeks, without the need for ribavirin, Gilead Sciences announced on Wednesday. The results ... Faldaprevir all-oral regimen shows 100% response rate for people with HCV 1a in interim analysis Liz Highleyman / 02 December 2013 An interferon-free regimen of faldaprevir, deleobuvir and PPI-668 led to a 4-week post-treatment sustained virological response (SVR4) in treatment-naive patients with hard-to-treat HCV subtype 1a in an ongoing phase 2 trial, according to ... Daclatasvir + asunaprevir cures 85% of genotype 1b hepatitis C patients in Japanese study Liz Highleyman / 27 November 2013 An interferon- and ribavirin-free oral regimen of daclatasvir plus asunaprevir taken for 24 weeks led to sustained virological response (SVR12) in 85% of Japanese patients with hepatitis C virus subtype 1b, according to ... AbbVie reports 96% cure rate for interferon-free hepatitis C regimen in phase 3 study Keith Alcorn / 18 November 2013 An interferon-free combination of three drugs plus ribavirin achieved a sustained virologic response (SVR12) in 96% of previously untreated patients with genotype 1 hepatitis C infection, AbbVie reported in a press release on ... Fixed-dose sofosbuvir/ledipasvir with or without ribavirin cures most genotype 1 hepatitis C patients, LONESTAR study shows Liz Highleyman / 13 November 2013 At least 95% of newly treated people with genotype 1 hepatitis C and prior non-responders achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to ... BMS interferon-free combination cures over 90% of genotype 1 hepatitis C in 12 weeks Keith Alcorn / 06 November 2013 A combination of three direct-acting antivirals developed by Bristol-Myers Squibb cured chronic hepatitis C infection in over 90% of previously untreated patients in a mid-stage study, Gregory Everson of the University of Colorado ... AbbVie's two-drug, interferon-free combination cures genotype 1b hepatitis C infection in 95% Keith Alcorn / 05 November 2013 A two-drug combination of direct-acting antivirals developed by AbbVie achieved sustained virologic response in 95% of previously untreated patients with genotype 1b hepatitis C infection after 12 weeks of treatment, without the need ... Merck interferon-free combination shows high hepatitis C cure rate in early study Keith Alcorn / 05 November 2013 A two-drug combination of direct-acting antivirals developed by Merck achieved very high cure rates, with and without ribavirin, in patients with genotype 1 hepatitis C infection in a small study presented on Sunday ... ← Prev1...34567Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive